Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
August 23, 2023 10:30 ET
|
Tiziana Life Sciences Ltd.
Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the...
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
August 23, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences informiert über ein Live-Interview mit dem renommierten Wissenschaftler Dr. Howard L. Weiner bei Bloomberg TV, in dem er über die IND-Freigabe der FDA für intranasales Foralumab bei der Alzheimer-Krankheit spricht
August 18, 2023 04:30 ET
|
Tiziana Life Sciences Plc
NEW YORK, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) („Tiziana“ oder das „Unternehmen“), ein Biotechnologieunternehmen, das bahnbrechende Immunmodulationstherapien...
Tiziana Life Sciences annonce un entretien en direct sur Bloomberg TV avec le Dr Howard L. Weiner, renommé scientifique, afin de discuter de l'autorisation de la demande de nouveau médicament expérimental auprès de la FDA relative au foralumab intranasal pour la maladie d'Alzheimer
August 18, 2023 04:30 ET
|
Tiziana Life Sciences Plc
NEW YORK, 18 août 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq : TLSA) (« Tiziana » ou la « Société »), une société biotechnologique développant des traitements...
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
August 17, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
August 15, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to be overseen by Brigham and Women’s Hospital, a founding...
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
July 21, 2023 16:15 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel...
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
June 13, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences meldet Verringerung der mikroglialen Aktivierung bei insgesamt 5 von 6 an nicht-aktiver sekundär progredienter Multipler Sklerose erkrankten Patienten mit erweitertem Zugang zu intranasalem Foralumab
June 06, 2023 09:03 ET
|
Tiziana Life Sciences Plc
Die Ergebnisse bestätigen das positive Signal, das zuvor bei den ersten beiden Patienten mit erweitertem Zugang berichtet wurde, die beide anschließend klinische Verbesserungen zeigtenPhase-IIa-Studie...
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
June 05, 2023 10:00 ET
|
Tiziana Life Sciences Ltd.
Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvementsPhase 2a trial in na-SPMS on track to begin in Q3...